Provided by Tiger Fintech (Singapore) Pte. Ltd.

PepGen Inc.

1.50
-0.0200-1.32%
Post-market: 1.500.00000.00%16:50 EDT
Volume:118.73K
Turnover:176.69K
Market Cap:49.08M
PE:-0.48
High:1.51
Open:1.51
Low:1.44
Close:1.52
Loading ...

PepGen Inc: Will Focus Efforts on Ongoing Connect1-Edo51 Study of Pgn-Edo51 in Dmd

THOMSON REUTERS
·
04 Mar

PepGen Inc - to Pause Phase 2 Connect2-Edo51 Study in Dmd Patients

THOMSON REUTERS
·
04 Mar

PepGen Announces Update to Phase 2 Connect2-Edo51 Study in Patients With Dmd

THOMSON REUTERS
·
04 Mar

PepGen Inc - No New Safety Issues Observed in Pgn-Edo51 Program

THOMSON REUTERS
·
04 Mar

PepGen Announces Update to Phase 2 CONNECT2-EDO51 Study in Patients with DMD

Business Wire
·
04 Mar

Promising Prospects for PepGen Inc.: Buy Rating Affirmed Amid Positive DM1 Treatment Developments

TIPRANKS
·
27 Feb

PepGen Inc. Reports Positive Trial Results and Financials

TIPRANKS
·
26 Feb

Sell Rating on PepGen Inc. Amid Clinical and Regulatory Challenges

TIPRANKS
·
25 Feb

Sector Update: Health Care Stocks Advance Late Afternoon

MT Newswires Live
·
25 Feb

Top Midday Gainers

MT Newswires Live
·
25 Feb

PepGen Price Target Maintained With a $16.00/Share by HC Wainwright & Co.

Dow Jones
·
25 Feb

PepGen data ‘very encouraging’ for program, says H.C. Wainwright

TIPRANKS
·
25 Feb

PepGen initial DM1 data ‘a clear win,’ says Stifel

TIPRANKS
·
24 Feb

PepGen Inc. Announces Positive FREEDOM-DM1 Trial Results

TIPRANKS
·
24 Feb

BRIEF-PepGen Q4 Operating Expenses USD 24.345 Million

Reuters
·
24 Feb

PepGen Q4 Operating Income USD -24.345 Million

THOMSON REUTERS
·
24 Feb

PepGen Inc - Q4 Loss per Share $0.68

THOMSON REUTERS
·
24 Feb

Press Release: PepGen Reports Fourth Quarter and Year-End 2024 Financial Results and Recent Corporate Highlights

Dow Jones
·
24 Feb

PepGen Inc - Results From Freedom 15 Mg/Kg Cohort Expected in H2 2025

THOMSON REUTERS
·
24 Feb

PepGen Inc - Mean Splicing Correction of 29.1% at 10 Mg/Kg Dose

THOMSON REUTERS
·
24 Feb